Budget impact analysis of breast cancer medications: a systematic review

BACKGROUND: Breast cancer (BC) is the most common cancer globally among women, with 2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both. BC subtype guides the standard systemic therapy administered, which consists of endocrine therapy for all HR + tumors, trastuzum...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadnezhad, Ghader, Sattarpour, Melika, Moradi, Najmeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801587/
https://www.ncbi.nlm.nih.gov/pubmed/36581921
http://dx.doi.org/10.1186/s40545-022-00493-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801587/
https://www.ncbi.nlm.nih.gov/pubmed/36581921
http://dx.doi.org/10.1186/s40545-022-00493-1

Ejemplares similares